Artal Group’s Oric Pharmaceuticals ORIC Stock Holding History

Artal Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400,000	Closed	-$2.36M	–	135
2022 Q4	$2.36M	Hold	400,000	–	–	0.13%	83
2022 Q3	$1.28M	Hold	400,000	–	–	0.05%	106
2022 Q2	$1.79M	Hold	400,000	–	–	0.1%	103
2022 Q1	$2.14M	Hold	400,000	–	–	0.09%	111
2021 Q4	$5.88M	Hold	400,000	–	–	0.16%	97
2021 Q3	$8.36M	Hold	400,000	–	–	0.19%	90
2021 Q2	$7.08M	Buy	400,000 +300,000	+300%	+$6.57M	0.14%	110
2021 Q1	$2.45M	Hold	100,000	–	–	0.04%	138
2020 Q4	$3.38M	Sell	100,000 -42,500	-30%	-$1.22M	0.07%	116
2020 Q3	$3.56M	Sell	142,500 -7,500	-5%	-$179K	0.09%	108
2020 Q2	$5.06M	Buy	+150,000	New	+$4.79M	0.14%	105

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Artal Group's ORIC Position: Q1 2023 in Review

Artal Group sold out of Oric Pharmaceuticals (ORIC) in Q1 2023, closing a stake of 400,000 shares — an estimated $2.36M sold.

Artal Group first reported a position in ORIC in Q2 2020 and held it in 11 quarters. The position peaked at $8.36M in Q3 2021. 70 funds tracked by Wall St. Rank hold ORIC as of Q1 2023.

Artal Group reported no remaining Oric Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Artal Group sold 400,000 Oric Pharmaceuticals shares in Q1 2023, an estimated $2.36M.
Artal Group first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 11 quarters.
Artal Group's Oric Pharmaceuticals position peaked at $8.36M in Q3 2021.
70 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.